Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We tested the cyclophosphamide effects against the growth of adenovirus-transformed cells and the subsequent tumor development in the syngeneic host. Cyclophosphamide did not show any effect on the tumor evolution when injected 24 and 6 hours before cell implantation. Cyclophosphamide injected 24 or 39 hours after cell implantation prevented or retarded the tumor growth. In mice bearing palpable tumors, it induced their complete regression in 85,7% of the animals, but did not effect the development of the homograft immunity.
 ...
PMID:Effect of cyclophosphamide on syngeneic transplantation of adenovirus 12-transformed tumor cells in C3H/he mice. 2 Sep 3

The survival time of animals, inhibition of the incorporation of thymidine-[6-3H] (3H-TdR) into DNA, and histopathological observation were made after the injection of Mitomycin-C, Bleomycin, cyclophosphamide, Daunomycin, Actinomycin-D, or 5-fluorouracil into mice transplanted with sarcoma-180 to their liver, kidney, and lung. The most prolonged survival time was obtained by the injection with cyclophosphamide and a moderate prolonged survival by Bleomycin and Actinomycin-D. In the case of 5-fluorouracil and Daunomycin, there were extreme variations in the survival time depending on the site of tumor growth. Cyclophosphamide and 5-fluorouracil showed greater and longer lasting inhibition of the incorporation of 3H-TdR into DNA of the tumor tissue, whereas the remaining agents caused transient inhibition on the tumor tissue. Inhibitory ratio and duration of the incorporation of 3H-TdR into DNA of normal site of the tissue of tumor-bearing organ were found to be more increased or almost the same compared with those of the tumor tissue. The most rapid recovery of the incorporation of 3H-TdR into DNA was observed in the small intestine among various organs and tumor in any treatment groups. From the histopathological observation, the degree of tumor cell damage by the agent was almost in agreement with inhibition of the incorporation of 3H-TdR up to 72 hr after the treatment.
 ...
PMID:Effect of antitumor agents on sarcoma-180 tumor cells transplanted to liver, kidney, and lung. 5 69

Lymphoid leukosis (LL), a neoplasm of the bursa-dependent lymphoid cells of the chicken, was induced by Rous-associated virus-1 in susceptible chickens. Cyclophosphamide (CY), which destroyed the lymphoid elements of the bursa of Fabricius and abrogated humoral immunity, prevented LL. Concomitantly, osteopetorosis and other neoplasms increased. Transfer of bursa cells from chickens into CY-treated hatchmates restored immune competence. Birds whose B-cell functions were reconstituted died of LL and were less likely to die of osteopetrosis and other neoplasms than were CY-treated chicks. These results suggested that the bursa cell transferred into the CY-treated chicks were the target cells for lymphoid leukosis transformation.
 ...
PMID:Lymphoid leukosis in chickens chemically bursectomized and subsequently inoculated with bursa cells. 5 19

Even though Bleomycin is excreted in the urine in high concentrations, side effects in the urinary tract due to the chemical nature of this compound are seldom observed. With respect to treatment of gynecological carcinomas, it is, therefore, important to examine the effect that Bleomycin when treatment involves the use of Endoxan. Cytologically, one finds an increase in desquanmation of the transitional epithelium and an increase in degenerate cell forms. The homogenous eosinophilic cellular inclusions which are observed, are specific for neither Endoxan nor for Bleomycin treatment. The antibiotic effect of Bleomycin results in an aseptic cystitis. The urocytogramm is suitable for examining the epithelial changes of the urinary tract in context with the gynecological carcinoma treatment and also for determing tumor breakthough into the bladder.
 ...
PMID:[Urocytogram in the treatment with bleomycin]. 5 14

The C1300 murine neuroblastoma system has been studied to determine its relevance as a chemotherapy model to the human disease. Studies using combination therapy revealed that BCNU/cyclophosphamide combination therapy increased the median lifespan 300% in A/J mice bearing the C1300 tumor. Cyclophosphamide/imidazole carboxamide and adriamycin/imidazole carboxamide combinations were less active, increasing median lifespans 189% and 144%, respectively. Vincristine/bleomycin were inactive even when the schedule was adjusted to coincide with the time of maximum mitoses following vincristine injections. These results suggest the BCNU/cyclophosphamide combination chemotherapy may be effective in human disease.
 ...
PMID:Combination chemotherapy in murine neuroblastoma. 6 76

Acute myelogenous leukemia (AML) of the inbred Wistar/Furth (W/Fu) rat is pathophysiologically similar to human AML. Subcutaneous transplantation of 1.0 X 10(6) cells of a clonal tissue culture line of W/Fu AML into 6- to 8-week-old rats produced local myeloblastomas in 8--10 days which progressed to infiltration of regional nodes, replacement of greater than 90% of the bone marrow, ascites, and fatal peripheral blood leukemia with concomitant hyperlysozymemia. Single doses of adriamycin, daunomycin, actinomycin, cytosine arabinoside, or Cytoxan in rats with 1.0 cm myeloblastomas produced complete tumor regression while bu-sulfan, vinblastine, vincristine, dexamethasone, and Methotrexate was relatively ineffective. Responses were associated with delay in progression to peripheral blood leukemia and prolonged survival. Similar results were obtained following treatment of rats with already disseminated leukemia. The demonstration of response to drugs known active against human AML indicates that the W/Fu AML should be a valuable model for rapid evaluation of new chemotherapeutic agents for clinical use.
 ...
PMID:Chemotherapeutic remissions in Wistar Furth rat acute myelogenous leukemia: a model for human AML. 6 30

The original metal-salt technique of Gomori (1948a) employing p-chloranilidophosphonic acid as a substrate for the demonstration of the activity of phosphoamidase has been used with varying success by a number of investigators for light microscopy. Cyclophosphamide (endoxan) which is a cytotoxic drug known to activate phosphoamidase and other lysosomal enzymes in neoplasm (Grillo, 1971) is proposed as another substrate for the enzyme for both light and electron microscopy.
 ...
PMID:Light and electron histochemistry of phosphoamidase with p-chloranilidophosphonic acid and with cyclophosphamide (endoxan). 8 80

There is agreement that the morbidity and mortality of CPA tumors are directly proportional to the size of the tumor. The diagnostic difficulty, however, is indirectly proportional to the size: the large tumors are diagnosed with little difficulty, the smaller ones with considerable challenge. In the search for these tumors, it is apparent that the incidence of all sizes is low. To arrive at the diagnosis, efforts must be pursued in any patient with unilateral sensorineural hearing loss, unilateral tinnitus, or vertigo. In the past 12 years, 19,000 new patients were seen in the office of the Pittsburgh Otological Association. In this new patient population, 120 tumors were proven by surgery. Six others (bilateral tumors) were diagnosed but not operated on, and four others were diagnosed but were operated on elsewhere for a total of 130 patients. An estimate of the cost of diagnosing these tumors is presented. Consideration is given to the cost-benefit ratio of diagnosing those diseases which must be considered also in the differential diagnosis when the above symptoms are present. These are: congenital changes, trauma, metabolic neuropathies, Meniere's disease, noise-induced hearing loss, lues, sudden hearing loss, and unilateral symptoms of undetermined etiology.
 ...
PMID:Cost-benefit ratio in our search for cerebellopontine angle tumors. 10 80

Twenty-four patients with far advanced malignant tumors, resistent to established chemotherapy,, were treated with the combination of MNU and Cyclophosphamide. The drugs were administered in six-day cycles sequentially. MNU in doses of 4 mg/kg body weight and Cyclophosphamide in doses of 8 mg/kg body weight were given. Results of treatment showed response (greater than 50% tumor regression) in 10 (42%) of the 24 treated patients. Seven remissions were complete and three partial. Patients with Hodgkin's disease, malignant melanoma and breast cancer responded to this combination chemotherapy. Objective remissions were obtained also in five of thirteen patients with primary or metastatic brain tumors and in five of nine patients with pulmonary metastases. Nausea and vomiting were the main toxic effects, especially after injections of MNU. Myelosuppression was noted in about 50% of treated patients. Since this combination of cytostatics showed significant antitumor activity, further investigations are necessary on a larger number of patients and in other types of malignant tumors.
 ...
PMID:Combination chemotherapy with 1-methyl-1-nitrosourea (MNU) and cyclophosphamide in solid tumors. 14 13

Hydron pouches were applied in three cases of embryonal hepatomas in infants. Cyclophosphamide (one case) and methotrexate (two cases) were used for filling of pouches in order to accomplish local chemotherapeutical effect directly on the tumor. Histopathological examination showed good compatibility of pouches to the liver tissue. No therapeutical effect was observed in a set of experiments due to a small size of pouches as compared to big masses of tumor. Some suggestions for further development of this method are presented.
 ...
PMID:The experience with clinical application of hydron pouches in tumor chemotherapy. 16 91


1 2 3 4 5 6 7 8 9 10 Next >>